067370.Kq
The company is a pharmaceuticals firm that generates revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
Business. The company is a pharmaceuticals firm that generates revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company is a pharmaceuticals firm that generates revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
The company maintains a capital structure with a debt-to-equity ratio of 0.98, indicating a relatively balanced mix of debt and equity financing. Its liquidity position is assessed as medium, with a current ratio of 0.53, suggesting that the company may face challenges in meeting short-term obligations with its current assets. The price-to-book ratio of 2.58 and the price-to-tangible-book ratio of 2.58 indicate that the company's market value is significantly higher than its book value, which may reflect strong intangible assets or market expectations.
In terms of profitability, the company's return on equity (ROE) of 9.68% and return on assets (ROA) of 4.6% are key indicators of its efficiency in generating profits from shareholders' equity and total assets, respectively. These figures should be compared to the industry median to determine if the company is outperforming or underperforming its peers. The company's operating margin, calculated as operating income divided by revenue, is 36.8%, which is a strong indicator of its operational efficiency.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may expose the company to higher risks if the segment or region experiences a downturn. The company's revenue for the latest period is 13,672,512,810 KRW, and its growth trajectory is expected to follow the industry's general trend, with no specific numeric deltas provided for the current or next fiscal year.
The risk assessment indicates a low potential for dilution, with no immediate pressure for share issuance. However, the company's net cash position is negative after subtracting total debt, which could affect its financial flexibility. The company has not disclosed any recent significant events in its filings or transcripts that would directly impact its financial performance or strategic direction.
The company's capital expenditures for the latest period were -3,238,868,800 KRW, indicating a reduction in capital spending. This could be a strategic move to preserve cash or a reflection of the company's current capital needs. The company's operating cash flow of 3,815,501,400 KRW and free cash flow of 1,354,284,310 KRW suggest that it is generating sufficient cash from operations to support its ongoing activities and potentially fund future growth.
- The company has a balanced capital structure with a debt-to-equity ratio of 0.98.
- The company's ROE of 9.68% and ROA of 4.6% indicate strong profitability relative to its equity and assets.
- The company's liquidity position is medium, with a current ratio of 0.53.
- The company's price-to-book ratio of 2.58 suggests that the market values the company higher than its book value.
- The company's operating margin of 36.8% reflects efficient operations.
- The company's negative net cash position after subtracting total debt may affect its financial flexibility.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 067370.KQ Market data — financials · 2026-05-26